Vision Loss News and Research

RSS

New myopia control technology for eye health benefits from Vision CRC

Scientists from the Vision Cooperative Research Centre in Australia have announced that myopia, or short-sightedness, can be controlled with new technology. This ground breaking discovery was based on research conducted by Vision CRC partners – the University of Houston College of Optometry and the Brien Holden Vision Institute, located at the University of New South Wales.

15 Jul 2010

Silicon oil appears to protect vision in patients undergoing radiation therapy for ocular melanoma: Study

Eye cancer patients face an unenviable dilemma. They must enter treatment knowing that their surgeon's strategy to kill the deadly tumor with radiation may also sacrifice their eyesight.

13 Jul 2010

Japanese scientists identify long-elusive enzyme necessary for proper regulation of cilia

It's safe to say that cilia, the hairlike appendages jutting out from the smooth surfaces of most mammalian cells, have long been misunderstood - underestimated, even.

8 Jul 2010

FDA approves IMT to improve vision in patients with end-stage AMD

The U.S. Food and Drug Administration today announced it has approved the Implantable Miniature Telescope to improve vision in some patients with end-stage age-related macular degeneration.

7 Jul 2010

Healthy diet can reduce age-related eye problems

While 20/20 vision is a symbol of visual acuity, between now and the year 2020, more and more people will experience some extent of vision loss due to age-related macular degeneration (AMD) and other sight-robbing diseases.

2 Jul 2010

pSivida's licensee submits NDA to FDA for Iluvien

pSivida Corp., a leader in the development of sustained release back of the eye drug delivery systems for difficult-to-treat conditions, today announced that its licensee, Alimera Sciences has submitted a New Drug Application to the U.S. Food and Drug Administration for Iluvien for Diabetic Macular Edema.

1 Jul 2010

Study: Near-normal glucose control does not delay risk of organ damage in diabetes patients

In people with longstanding type 2 diabetes who are at high risk for heart attack and stroke, lowering blood sugar to near-normal levels did not delay the combined risk of diabetic damage to kidneys, eyes, or nerves, but did delay several other signs of diabetic damage, a study has found. The intensive glucose treatment was compared with standard glucose control.

30 Jun 2010

Study highlights importance of individualized, patient-centered therapies

In an analysis from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, one of the largest studies of its kind to determine whether intensive blood glucose (sugar) control worked better than standard blood sugar control among diabetics, results show that the benefits of intensive therapy need to be balanced against the increase in total and cardiovascular disease-related death, increased weight gain, and high risk for severe low blood sugar.

30 Jun 2010

Study indicates two treatment strategies can reduce progression of diabetic retinopathy

In high-risk adults with type 2 diabetes, researchers have found that two therapies may slow the progression of diabetic retinopathy, an eye disease that is the leading cause of vision loss in working-age Americans.

30 Jun 2010

AqueSys secures $35 million in Series C financing round

AqueSys, Inc., a medical device company that develops, manufactures and distributes proprietary implants for glaucoma, today announced that it has secured $35 million in Series C financing. The round was led by Longitude Capital and Rho Ventures, with participation from existing investors Accuitive Medical Ventures, The Carlyle Group and SV Life Sciences.

30 Jun 2010

Genentech's Lucentis for treatment of macular edema following RVO receives FDA approval

Genentech, Inc., a member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) has approved Lucentis® (ranibizumab injection) for the treatment of macular edema following retinal vein occlusion (RVO). The FDA approved this new indication after a six-month Priority Review.

23 Jun 2010

First clinical trial results of XOMA 052 in patients with uveitis of Behcet's disease presented at EULAR 2010

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced positive results from an open-label pilot study of XOMA 052 in patients with uveitis of Behcet's disease who were suffering from vision-threatening exacerbations despite maximal doses of immunosuppressive medicines.

17 Jun 2010

UH, AOA partner to get the word out about summer eye care, protection against UVR

As summer approaches, most people step up skin protection from harmful ultraviolet rays, yet aren't as vigilant about their eyes. Optometrists at the University of Houston are involved in a campaign to change this way of thinking.

15 Jun 2010

Research on genetic mutations could lead to accurate diagnosis of USH, says scientist

Usher syndrome, an inherited condition involving both hearing and vision loss, is not a simply recessively inherited disease, a scientist will tell the annual conference of the European Society of Human Genetics today (Saturday). Dr. Hanno Bolz, Associate Medical Director of the Bioscientia Centre for Human Genetics, Ingelheim, Germany, and active in teaching and research at the University Hospital of Cologne, will say that his team's research challenges the traditional view that USH was inherited as a single gene disorder, and shows that it may result from at least two different genetic mutations.

14 Jun 2010

Ranibizumab improves vision in patients with visual impairment due to DME: RESTORE study

Results from a new major diabetes eye health study may have the potential to change the way vision loss due to diabetic macular edema, a serious and devastating complication of diabetes, is treated. One year results from the RESTORE study show that 37 per cent of patients treated with ranibizumab only and 43 per cent of those treated with ranibizumab plus laser therapy, had a significant improvement in visual acuity of 10 letters or more on an eye chart, compared to 16 per cent of patients treated with laser alone - the current standard treatment for visual impairment due to DME.

7 Jun 2010

RTU announces phase 2 clinical trial results of UF-021 in patients with retinitis pigmentosa

Sucampo Pharmaceuticals, Inc. today confirmed that its partner, R-Tech Ueno, Ltd. reported the results of its recently completed phase 2 clinical trial of UF-021 in retinitis pigmentosa patients. The results showed improvement in visual function dose-dependently in both visual field test and subjective findings.

5 Jun 2010

New study holds promise for patients with LCA

A new study led by Dr. Robert Koenekoop at the Montreal Children's Hospital at the McGill University Health Centre holds promise for certain patients with Leber congenital amaurosis, an inherited retinal degenerative disease that causes significant vision loss from birth. The study, sponsored by Canadian company QLT Inc., is designed to treat patients with LCA due to genetic mutations in either retinal pigment epithelium protein 65 or lecithin:retinol acyltransferase.

27 May 2010

New book to prevent Age-Related Macular Degeneration

A new prevention tool is now available, in both French and English, at local bookstores and pharmacies. Dr. Jean-Daniel Arbour and Dr. Pierre Labelle of the Universit- de Montr-al Department of Ophthalmology, along with two colleagues from France, have authored a new book to prevent vision loss, AMD: Age-Related Macular Degeneration (Annika Parance Publisher; 121 pages). Written to educate readers about the importance of vision health, the book provides clear explanations on the causes, consequences and treatments of AMD.

26 May 2010

Study: When incentive payments are removed, quality of health care suffers

Los Angeles Times: Researchers in Britain teamed with Kaiser Permanente in Northern California "to see what happened in Northern California when the health giant stopped rewarding doctors who screened patients for diabetic retinopathy and cervical cancer."

13 May 2010

Telemedical Retinal Image Analysis and Diagnosis technology permits early detection of diabetic retinopathy

Automated Medical Diagnostics, a startup company based in Memphis, envisions its product helping to preserve the sight of millions of people at risk of vision loss from diabetic retinopathy.

7 May 2010

Vision Loss News and Research

New myopia control technology for eye health benefits from Vision CRC

Silicon oil appears to protect vision in patients undergoing radiation therapy for ocular melanoma: Study

Japanese scientists identify long-elusive enzyme necessary for proper regulation of cilia

FDA approves IMT to improve vision in patients with end-stage AMD

Healthy diet can reduce age-related eye problems

pSivida's licensee submits NDA to FDA for Iluvien

Study: Near-normal glucose control does not delay risk of organ damage in diabetes patients

Study highlights importance of individualized, patient-centered therapies

Study indicates two treatment strategies can reduce progression of diabetic retinopathy

AqueSys secures $35 million in Series C financing round

Genentech's Lucentis for treatment of macular edema following RVO receives FDA approval

First clinical trial results of XOMA 052 in patients with uveitis of Behcet's disease presented at EULAR 2010

UH, AOA partner to get the word out about summer eye care, protection against UVR

Research on genetic mutations could lead to accurate diagnosis of USH, says scientist

Ranibizumab improves vision in patients with visual impairment due to DME: RESTORE study

RTU announces phase 2 clinical trial results of UF-021 in patients with retinitis pigmentosa

New study holds promise for patients with LCA

New book to prevent Age-Related Macular Degeneration

Study: When incentive payments are removed, quality of health care suffers

Telemedical Retinal Image Analysis and Diagnosis technology permits early detection of diabetic retinopathy

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News